Leading clinical trials technology platform provider Medable announced a new partnership with Nova Scotia Health Innovation Hub for a two-year pilot study to improve oncology trial access for patients in rural Nova Scotia through Medable’s decentralized clinical trial (DCT) platform.
Nova Scotia is Canada’s second smallest province by area. Almost 50 percent of Nova Scotians live in rural communities with a population less than 1,000. Access to follow-up care and clinical trials can thus be a challenge for patients living in remote areas of the province. With few trial locations nearby, this can lead to long travel times to sites and high associated costs for patients.
Medable said the long-term aim of the partnership is to improve patient access and trial diversity across Canada through its DCT technology.
Medable’s DCT platform, founded in 2015, offers trial sponsors (including pharma and biotech companies) and clinical research organizations (CROs) features that include AI and machine learning-driven patient identification and site selection; digitized patient enrollment; and the ability to conduct trials in any language and country. The technology offers remote patient monitoring, telehealth, access to patient data in real-time and streaming data.
Last year, Medable was named a leader in DCT products assessment for the second year in a row by Everest Group.
XTALKS WEBINAR: The Digital Future is Now: Making Patient Choice a Reality
Register for this free on-demand webinar to learn about the latest approaches for the integration of digital technologies in clinical trials, particularly within the context of increased decentralized clinical trial (DCT) landscapes. This webinar features industry experts from Medable, Syneos and Veeva who share best practices and examples on how to successfully implement and scale patient-first DCTs across an organization to drive transformation of the clinical development process while mitigating potential risks.
Medable’s DCT platform includes solutions such as Total Consent Management and Televisit, which enable patients to connect with physicians from their homes remotely to access care.
The pilot study will involve differentiated thyroid cancer patients.
“We face numerous challenges to providing holistic care, including geographic distance, recruiting diverse patients and a shortage of clinical researchers,” said Dr. Ali Imran, the principal investigator on the study and physician at Nova Scotia Health, in a news release from Medable. “With Medable, my patients will continue to get the best care, wherever they live. This is the future of clinical research, and I am honored to play my part.”
Nova Scotia Health conducts approximately 400 clinical trials every year and says it hopes this strategy will empower primary care providers (PCP) to be more involved with their patients post-trial through a shared care model, supported by DCT technologies.
Medable’s decentralized and hybrid trial solutions have enabled trial improvements such as 200 percent faster enrollment and 50 percent cost reductions.
“The success of this pilot stands to be a game-changer far beyond the borders of Nova Scotia,” said Michelle Longmire, co-founder and CEO of Medable. “Our technologies will empower a shared care model where PCPs will provide long-term oncology monitoring and care that was previously only possible through specialists — to the detriment of patient experience and outcomes. The potential benefits are vast — from improved prevention of cancer recurrence to increased diversity in clinical research.”
Medable software-as-a-service platform has been leveraged in more than 300 decentralized and hybrid clinical trials in 60 countries, serving more than one million patients and research participants globally.
Join or login to leave a comment
JOIN LOGIN